Tsamis, Konstantinos I; Mytilinaios, Dimitrios; Heneghan, Michael; Gillmore, Julian D; Gilbertson, Janet A; Giannopoulos, Sotirios; Sarmas, Ioannis; Tsamis, Konstantinos I; Mytilinaios, Dimitrios; Heneghan, Michael; Gillmore, Julian D; Gilbertson, Janet A; Giannopoulos, Sotirios; Sarmas, Ioannis; Konitsiotis, Spyridon; - view fewer (2023) Treatment of Acquired Transthyretin Amyloidosis in Domino Liver Transplantation. Clinical Transplantation , 37 (1) , Article e14822. 10.1111/ctr.14822.

Preview

Text Gillmore_Treatment of Acquired Transthyretin Amyloidosis in Domino Liver Transplantation_VoR.pdf Download (511kB) | Preview

Abstract

BACKGROUND: Domino liver transplantation (DLT) has been commonly used during the last two decades to partly meet the high need for liver transplants. However, the recipients of grafts from patients with noncirrhotic inherited metabolic disorders may ultimately develop metabolic syndrome, and management is usually intricate, being complicated by the underlying initial disorder, other comorbidities, and post-transplantation conditions. CASE: We report here the management and the outcome in a patient with acquired transthyretin amyloidosis after DLT and significant comorbidities. Final treatment with a transthyretin gene silencing agent, patisiran, was well tolerated and resulted in remission of the aggravating neurological deficits in a follow-up period of two years. CONCLUSIONS: The case presented here supports the concept that patisiran can target the hepatocytes producing the mutated transthyretin in acquired transthyretin amyloidosis, as efficiently as in hereditary transthyretin amyloidosis, and can be used to treat patients with transthyretin amyloidosis after DLT. This article is protected by copyright. All rights reserved.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item